09/02/2018 22:26:22

Adamas Announces New Employment Inducement Grant

Related content
08 Aug - 
Adamas Announces New Employment Inducement Grant
02 Aug - 
Adamas Reports Second Quarter 2018 Financial Results
01 Aug - 
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,..

EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of the company’s common stock, at a per share exercise price of $36.49, the closing trading price on February 7, 2018, and restricted stock units to acquire 8,625 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial-onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Ashleigh Barreto         

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sophos Sweeps Network and Endpoint Security Categories in CRN’s 2018 Annual Report Card – Again!
2
SHAREHOLDER ALERT: FIZZ ACAD FB ABBV TTPH RMTI HMNY GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
3
SHAREHOLDER ALERT: MRCY GLCNF GLNCY MD COOL HAIR FPI SBGL NWL GOGO FLKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
4
Key Energy Services Announces Appointment of Rob Saltiel as New President and Chief Executive Officer
5
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 August 2018 13:32:42
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180816.1 - EUROWEB1 - 2018-08-20 14:32:42 - 2018-08-20 13:32:42 - 1000 - Website: OKAY